Sangamo Therapeutics (STU:GBY) Total Assets : €97.06 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Sangamo Therapeutics Total Assets?

Sangamo Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was €97.06 Mil.

During the past 12 months, Sangamo Therapeutics's average Total Assets Growth Rate was -29.20% per year. During the past 3 years, the average Total Assets Growth Rate was -44.30% per year. During the past 5 years, the average Total Assets Growth Rate was -28.20% per year. During the past 10 years, the average Total Assets Growth Rate was 22.50% per year.

During the past 13 years, Sangamo Therapeutics's highest 3-Year average Total Assets Growth Rate was 184.80%. The lowest was -60.30%. And the median was 6.15%.

Total Assets is connected with ROA %. Sangamo Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -90.59%. Total Assets is also linked to Revenue through Asset Turnover. Sangamo Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.07.

Sangamo Therapeutics Total Assets Historical Data

The historical data trend for Sangamo Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Total Assets Chart

Sangamo Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

771.49

638.90

531.01

151.60

97.06

Sangamo Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															151.60	118.64	86.41	100.25	97.06

Sangamo Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sangamo Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	21.745	+	75.316
	=	97.06

Sangamo Therapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	21.745	+	75.316
	=	97.06

Sangamo Therapeutics (STU:GBY) Total Assets Explanation

Total Assets is connected with ROA %.

Sangamo Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-89.372	/	( (100.248	+	97.061)	/ 2 )
	=	-89.372	/	98.6545
	=	-90.59 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sangamo Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	7.211	/	( (100.248	+	97.061)	/ 2 )
=	7.211	/	98.6545
=	0.07

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sangamo Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (STU:GBY) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

SGMO:USA 0R1D:UK GBY:Germany

Address

501 Canal Boulevard, Richmond, CA, USA, 94804

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics Headlines

No Headlines